PSI CRO expands in RTP, outlines growth into 2018

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/Hankimage9)
(Image: iStock/Hankimage9)
PSI CRO has purchased new office space in Research Triangle Park (RTP) as the company expects to grow locally and globally in 2018.

PSI is a privately-owned, full-service contract research organization (CRO) headquartered in Switzerland.

When the company made the move to RTP in 2016, Kayt Leonard, public relations specialist, PSI CRO, told us the CRO planned to occupy the building space for several years.

However, by the third quarter of 2017, the company outgrew this facility and has since purchased a new space in the area, which Leonard said can accommodate three times the amount of staff currently employed.

The company will move into the new offices in Durham following renovations, which are expected to be completed in the second quarter of 2018.

PSI opened several new offices throughout 2017, including those in Sydney, Seoul​, Taipei​, and Madrid​. It also moved its San Francisco-based operations to a larger office in the greater SFO area.

Olga Alfonsova, head of corporate development at PSI CRO said in Septembe​r that the company is “perfectly on track​” with its plans to expand in Asia Pacific.

Hong Kong will be the next opening Alfonsova explained, with an opening expected early next year.

In 2018, we’ll continue to grow both locally and abroad​,” Leonard said.

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers